查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1951933

多形性胶质母细胞瘤 (GBM) 治疗市场分析及预测（至 2035 年）：按类型、产品类型、技术、应用、最终用户、设备、疾病阶段、服务、部署类型和功能划分

Glioblastoma Multiforme (GBM) Treatment Market Analysis and Forecast to 2035: Type, Product, Technology, Application, End User, Device, Stage, Services, Deployment, Functionality
出版日期: | 出版商: Global Insight Services | 英文 366 Pages | 商品交期: 3-5个工作天内

价格
简介目录

多形性胶质母细胞瘤 (GBM) 治疗市场预计将从 2024 年的 36 亿美元成长到 2034 年的 81 亿美元，复合年增长率约为 10%。 GBM 治疗市场涵盖针对侵袭性脑肿瘤的治疗方法，包括手术、放射线治疗、化疗以及新兴的免疫疗法，旨在延长患者的生存期并提高其生活品质。分子诊断和个人化医疗的进步正在推动创新，而未被满足的医疗需求和高发病率则推动了市场成长。策略合作和研发投资对于开发新型治疗方法和改善治疗效果至关重要。

由于治疗方法的进步和研究投入的增加，胶质母细胞瘤（GBM）治疗市场持续发展。化疗是表现最佳的领域，其中Temozolomide因其能有效延长患者存活期而成为应用最广泛的药物。免疫疗法是表现第二好的领域，由于查核点抑制剂和疫苗疗法的良好前景，该领域发展势头强劲。这些创新正在重塑治疗模式，并为改善患者预后带来希望。放射线治疗仍然是GBM治疗的关键组成部分，立体定位放射放射线手术和调强放射线治疗（IMRT）提高了治疗精度，并最大限度地减少了对正常组织的损伤。外科治疗领域也取得了进展，微创手术技术和神经导航系统提高了切除的准确性。基因疗法和标靶药物递送系统等新兴治疗方法正引起广泛关注，反映了精准医疗的趋势。製药公司和研究机构之间的合作正在加速新型疗法的开发，为市场成长提供了广泛的机会。

市场区隔
类型 化疗、放射线治疗、标靶治疗、免疫疗法、肿瘤治疗领域
产品 药品、医疗设备及治疗方案
科技 基因疗法、奈米技术、生物技术
适应症 原发性母细胞瘤、续发性母细胞瘤、復发性胶质母细胞瘤
最终用户 医院、专科诊所、门诊手术中心及研究机构
装置 核磁共振扫描仪、CT扫描仪、PET扫描仪
阶段 早期、晚期、復发期
服务 咨询、诊断和治疗服务
实施表格 本机部署、云端部署、混合式部署
功能 诊断、治疗和监测功能

多形性胶质母细胞瘤 (GBM) 治疗市场充满活力，主要参与者之间的市占率分布差异显着。定价策略竞争激烈，反映了创新和新治疗方法的推出。近期推出的产品主要集中在标靶治疗和个人化医疗，旨在改善患者预后。市场正转向包括免疫疗法和基因编辑在内的新型治疗方法，这些方法正在重塑治疗模式，并为市场成长提供广阔前景。竞争基准研究显示，既有老牌製药巨头，也有新兴生技公司，它们都占据强大的市场地位。监管的影响，尤其是在北美和欧洲，对市场动态的塑造至关重要，严格的核准流程影响新产品上市的速度。竞争格局的特点是策略联盟和併购，这些措施增强了企业的研发能力和市场覆盖范围。法律规范不断完善，重点关注病人安全和疗效，这在推动创新的同时，也带来了合规性和市场准入的挑战。

主要趋势和驱动因素：

多形性胶质母细胞瘤 (GBM) 治疗市场正经历着蓬勃发展，这主要得益于发病率的上升和治疗方法的进步。关键趋势包括个人化医疗的发展，它能够根据个别基因谱进行治疗，从而提高疗效并改善患者预后。免疫疗法已成为一种极具前景的治疗选择，它利用人体自身的免疫系统更有效地攻击癌细胞。另一个关键驱动因素是研发活动的活性化，催生了创新的药物製剂和给药机制。製药公司与研究机构之间合作的加强正在加速新治疗方法的发现。此外，孤儿药的监管支持正在奖励GBM治疗方法的研发，进一步刺激市场扩张。新兴市场拥有完善的医疗基础设施，并且能够更便利地获得先进疗法，这些市场蕴藏着许多机会。专注于提供价格合理且易于获取的解决方案的公司将占据有利地位，从而抢占这个不断成长的市场。此外，人工智慧 (AI) 在药物研发和病患监测中的应用将透过提高治疗的精准性和效率，彻底改变 GBM 的治疗方式。随着人们对癌症研究的兴趣和投入不断增长，GBM 治疗市场有望持续进步和创新。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 化疗
    • 放射治疗
    • 标靶治疗
    • 免疫疗法
    • 肿瘤治疗领域
  • 市场规模及预测：依产品划分
    • 药物
    • 装置
    • 治疗方案
  • 市场规模及预测：依技术划分
    • 基因治疗
    • 奈米科技
    • 生物技术
  • 市场规模及预测：依应用领域划分
    • 原发性母细胞瘤
    • 次发性细胞瘤
    • 復发性胶质母细胞瘤
  • 市场规模及预测：依最终用户划分
    • 医院
    • 专科诊所
    • 门诊手术中心
    • 研究所
  • 市场规模及预测：依设备划分
    • 核磁共振扫描仪
    • CT扫描仪
    • PET扫描仪
  • 市场规模及预测：依疾病阶段划分
    • 早期
    • 高级阶段
    • 復发期
  • 市场规模及预测：依服务划分
    • 咨询服务
    • 诊断服务
    • 治疗服务
  • 市场规模及预测：依发展状况
    • 本地部署
    • 基于云端的
    • 杂交种
  • 市场规模及预测：依功能划分
    • 诊断特征
    • 按治疗功能
    • 监控功能

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章 公司简介

  • Kazia Therapeutics
  • Northwest Biotherapeutics
  • Del Mar Pharmaceuticals
  • Cortexyme
  • Vascular Biogenics
  • Agenus
  • Merrimack Pharmaceuticals
  • Diffusion Pharmaceuticals
  • Ziopharm Oncology
  • Oncoceutics
  • DNAtrix
  • Immunomic Therapeutics
  • Kintara Therapeutics
  • Medicenna Therapeutics
  • Candel Therapeutics
  • Immuno Cellular Therapeutics
  • Plus Therapeutics
  • Tocagen
  • Orbus Therapeutics
  • Bexion Pharmaceuticals

第九章：关于我们

简介目录
Product Code: GIS26463

Glioblastoma Multiforme (GBM) Treatment Market is anticipated to expand from $3.6 billion in 2024 to $8.1 billion by 2034, growing at a CAGR of approximately 10%. The Glioblastoma Multiforme (GBM) Treatment Market encompasses therapies targeting aggressive brain tumors, including surgery, radiation, chemotherapy, and emerging immunotherapies. It aims to extend patient survival and improve quality of life. Advances in molecular diagnostics and personalized medicine are driving innovation, while the high unmet need and prevalence spur market growth. Strategic collaborations and research investments are pivotal in developing novel treatments and enhancing therapeutic efficacy.

The Glioblastoma Multiforme (GBM) Treatment Market is evolving, driven by advancements in therapeutic approaches and increasing research investments. The chemotherapy segment leads in performance, with temozolomide being the most widely used due to its efficacy in extending patient survival. Immunotherapy is the second highest performing segment, gaining momentum with promising results from checkpoint inhibitors and vaccine-based therapies. These innovations are reshaping treatment paradigms, offering hope for improved patient outcomes. Radiation therapy remains a critical component of GBM treatment, with stereotactic radiosurgery and intensity-modulated radiation therapy enhancing precision and minimizing damage to healthy tissue. The surgical segment is also witnessing advancements, with minimally invasive techniques and neuro-navigation systems improving resection accuracy. Emerging treatment modalities, such as gene therapy and targeted drug delivery systems, are attracting significant interest, reflecting a shift towards personalized medicine. Collaborations between pharmaceutical companies and research institutions are accelerating the development of novel therapeutics, presenting lucrative opportunities for market growth.

Market Segmentation
TypeChemotherapy, Radiotherapy, Targeted Therapy, Immunotherapy, Tumor Treating Fields
ProductDrugs, Devices, Therapeutic Solutions
TechnologyGene Therapy, Nanotechnology, Biotechnology
ApplicationPrimary Glioblastoma, Secondary Glioblastoma, Recurrent Glioblastoma
End UserHospitals, Specialty Clinics, Ambulatory Surgical Centers, Research Institutes
DeviceMRI Scanners, CT Scanners, PET Scanners
StageEarly Stage, Advanced Stage, Recurrent Stage
ServicesConsultation Services, Diagnostic Services, Treatment Services
DeploymentOn-premise, Cloud-based, Hybrid
FunctionalityDiagnostic Functionality, Therapeutic Functionality, Monitoring Functionality

The Glioblastoma Multiforme (GBM) Treatment Market is characterized by a dynamic landscape with diverse market share distribution among key players. Pricing strategies are increasingly competitive, reflecting both innovation and the introduction of new treatment modalities. Recent product launches have focused on targeted therapies and personalized medicine, aiming to improve patient outcomes. The market is witnessing a shift towards novel therapeutic approaches, including immunotherapy and gene editing, which are reshaping treatment paradigms and offering promising avenues for growth. Competition benchmarking reveals a robust presence of established pharmaceutical giants alongside emerging biotech firms. Regulatory influences, particularly in North America and Europe, are pivotal in shaping market dynamics, with stringent approval processes impacting the speed of new product introductions. The competitive landscape is marked by strategic collaborations and mergers, enhancing research capabilities and market reach. Regulatory frameworks continue to evolve, with an emphasis on patient safety and efficacy, driving innovation while presenting challenges in compliance and market entry.

Geographical Overview:

The Glioblastoma Multiforme (GBM) treatment market is witnessing varied growth patterns across different regions. North America remains at the forefront, driven by advanced healthcare infrastructure and significant research investments. The presence of leading pharmaceutical companies and active clinical trials contributes to its dominance. Europe follows, benefiting from strong regulatory support and increasing healthcare expenditure. The region's focus on innovative therapies and personalized medicine further propels market growth. Asia Pacific is emerging as a lucrative market, with rising healthcare awareness and improving medical facilities. Countries like China and India are investing heavily in healthcare, fostering growth in GBM treatment. Latin America and the Middle East & Africa are nascent markets with promising potential. Brazil and South Africa are key countries showing increased interest in modern oncology treatments. Enhanced healthcare policies and growing patient awareness in these regions are expected to drive demand for advanced GBM therapies, creating new growth pockets in the global market.

The Glioblastoma Multiforme (GBM) Treatment Market is significantly influenced by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, reliance on imported pharmaceuticals prompts strategic shifts towards local R&D investments to mitigate tariff impacts. China's focus on self-sufficiency in drug production is accelerated by trade restrictions, fostering innovation in GBM therapies. Taiwan's robust biotech sector remains vital, yet faces geopolitical risks from regional tensions. Globally, the GBM treatment market is experiencing steady growth, driven by advancements in personalized medicine and immunotherapy. By 2035, market evolution will hinge on collaborative research and diversified supply chains. Middle East conflicts could exacerbate supply chain disruptions, indirectly affecting production costs and timelines through volatile energy prices.

Key Trends and Drivers:

The Glioblastoma Multiforme (GBM) Treatment Market is experiencing dynamic growth, propelled by increasing incidence rates and advancements in therapeutic approaches. A key trend is the development of personalized medicine, which tailors treatment based on individual genetic profiles, enhancing efficacy and patient outcomes. Immunotherapy is gaining traction as a promising treatment option, leveraging the body's immune system to combat cancer cells more effectively. Another significant driver is the rise in research and development activities, leading to innovative drug formulations and delivery mechanisms. The growing collaboration between pharmaceutical companies and research institutions is accelerating the pace of new treatment discoveries. Additionally, regulatory support for orphan drugs provides incentives for developing GBM therapies, fostering further market expansion. Opportunities abound in emerging markets where healthcare infrastructure is improving, and access to advanced treatments is expanding. Companies focusing on affordable and accessible solutions are well-positioned to capture these growing markets. The integration of artificial intelligence in drug discovery and patient monitoring is also set to revolutionize the landscape, offering precision and efficiency in GBM treatment. As awareness and investment in cancer research grow, the GBM Treatment Market is poised for sustained advancement and innovation.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Device
  • 2.7 Key Market Highlights by Stage
  • 2.8 Key Market Highlights by Services
  • 2.9 Key Market Highlights by Deployment
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Chemotherapy
    • 4.1.2 Radiotherapy
    • 4.1.3 Targeted Therapy
    • 4.1.4 Immunotherapy
    • 4.1.5 Tumor Treating Fields
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Drugs
    • 4.2.2 Devices
    • 4.2.3 Therapeutic Solutions
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 Gene Therapy
    • 4.3.2 Nanotechnology
    • 4.3.3 Biotechnology
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Primary Glioblastoma
    • 4.4.2 Secondary Glioblastoma
    • 4.4.3 Recurrent Glioblastoma
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Specialty Clinics
    • 4.5.3 Ambulatory Surgical Centers
    • 4.5.4 Research Institutes
  • 4.6 Market Size & Forecast by Device (2020-2035)
    • 4.6.1 MRI Scanners
    • 4.6.2 CT Scanners
    • 4.6.3 PET Scanners
  • 4.7 Market Size & Forecast by Stage (2020-2035)
    • 4.7.1 Early Stage
    • 4.7.2 Advanced Stage
    • 4.7.3 Recurrent Stage
  • 4.8 Market Size & Forecast by Services (2020-2035)
    • 4.8.1 Consultation Services
    • 4.8.2 Diagnostic Services
    • 4.8.3 Treatment Services
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-premise
    • 4.9.2 Cloud-based
    • 4.9.3 Hybrid
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Diagnostic Functionality
    • 4.10.2 Therapeutic Functionality
    • 4.10.3 Monitoring Functionality

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Device
      • 5.2.1.7 Stage
      • 5.2.1.8 Services
      • 5.2.1.9 Deployment
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Device
      • 5.2.2.7 Stage
      • 5.2.2.8 Services
      • 5.2.2.9 Deployment
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Device
      • 5.2.3.7 Stage
      • 5.2.3.8 Services
      • 5.2.3.9 Deployment
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Device
      • 5.3.1.7 Stage
      • 5.3.1.8 Services
      • 5.3.1.9 Deployment
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Device
      • 5.3.2.7 Stage
      • 5.3.2.8 Services
      • 5.3.2.9 Deployment
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Device
      • 5.3.3.7 Stage
      • 5.3.3.8 Services
      • 5.3.3.9 Deployment
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Device
      • 5.4.1.7 Stage
      • 5.4.1.8 Services
      • 5.4.1.9 Deployment
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Device
      • 5.4.2.7 Stage
      • 5.4.2.8 Services
      • 5.4.2.9 Deployment
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Device
      • 5.4.3.7 Stage
      • 5.4.3.8 Services
      • 5.4.3.9 Deployment
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Device
      • 5.4.4.7 Stage
      • 5.4.4.8 Services
      • 5.4.4.9 Deployment
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Device
      • 5.4.5.7 Stage
      • 5.4.5.8 Services
      • 5.4.5.9 Deployment
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Device
      • 5.4.6.7 Stage
      • 5.4.6.8 Services
      • 5.4.6.9 Deployment
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Device
      • 5.4.7.7 Stage
      • 5.4.7.8 Services
      • 5.4.7.9 Deployment
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Device
      • 5.5.1.7 Stage
      • 5.5.1.8 Services
      • 5.5.1.9 Deployment
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Device
      • 5.5.2.7 Stage
      • 5.5.2.8 Services
      • 5.5.2.9 Deployment
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Device
      • 5.5.3.7 Stage
      • 5.5.3.8 Services
      • 5.5.3.9 Deployment
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Device
      • 5.5.4.7 Stage
      • 5.5.4.8 Services
      • 5.5.4.9 Deployment
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Device
      • 5.5.5.7 Stage
      • 5.5.5.8 Services
      • 5.5.5.9 Deployment
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Device
      • 5.5.6.7 Stage
      • 5.5.6.8 Services
      • 5.5.6.9 Deployment
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Device
      • 5.6.1.7 Stage
      • 5.6.1.8 Services
      • 5.6.1.9 Deployment
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Device
      • 5.6.2.7 Stage
      • 5.6.2.8 Services
      • 5.6.2.9 Deployment
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Device
      • 5.6.3.7 Stage
      • 5.6.3.8 Services
      • 5.6.3.9 Deployment
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Device
      • 5.6.4.7 Stage
      • 5.6.4.8 Services
      • 5.6.4.9 Deployment
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Device
      • 5.6.5.7 Stage
      • 5.6.5.8 Services
      • 5.6.5.9 Deployment
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Kazia Therapeutics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Northwest Biotherapeutics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Del Mar Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cortexyme
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Vascular Biogenics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Agenus
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Merrimack Pharmaceuticals
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Diffusion Pharmaceuticals
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Ziopharm Oncology
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Oncoceutics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 DNAtrix
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Immunomic Therapeutics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Kintara Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Medicenna Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Candel Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Immuno Cellular Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Plus Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Tocagen
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Orbus Therapeutics
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Bexion Pharmaceuticals
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us